Corcept Therapeutics, Inc. (CORT) Stock Recommendation | Score, Valuation, Technicals & Financial Trend

Score

Click here to find our call on this stock

Strong Sell

Sell

Hold

Buy

Strong Buy

Comparison

Company

Score

Quality

Valuation

Financial

Technical

Apellis Pharmaceuticals, Inc.

Insmed, Inc.

ACADIA Pharmaceuticals, Inc.

Perrigo Co. Plc

Prestige Consumer Healthcare, Inc.

Amicus Therapeutics, Inc.

Corcept Therapeutics, Inc.

Organon & Co.

Cerevel Therapeutics Holdings, Inc.

MoonLake Immunotherapeutics

Bausch Health Cos., Inc.

Why is Corcept Therapeutics, Inc. ?

High Management Efficiency with a high ROE of 21.09%

Company has a low Debt to Equity ratio (avg) at times

Strong Long Term Fundamental Strength with an average Return on Equity (ROE) of 21.09%

Negative results in Sep 25

PRE-TAX PROFIT(Q) At USD 15.24 MM has Fallen at -51.69%
ROCE(HY) Lowest at 16.47%
NET PROFIT(Q) Lowest at USD 19.36 MM

With ROE of 16.56%, it has a expensive valuation with a 5.72 Price to Book Value

The stock is trading at a premium compared to its peers' average historical valuations
Over the past year, while the stock has generated a return of -33.66%, its profits have fallen by -25.5%

High Institutional Holdings at 80.97%

These investors have better capability and resources to analyse fundamentals of companies than most retail investors.

Underperformed the market in the last 1 year

Even though the market (S&P 500) has generated returns of 11.87% in the last 1 year, the stock has hugely underperformed and has generate negative returns of -33.66% returns

Real-Time Research Report

Verdict Report

How much should you hold?

Overall Portfolio exposure to Corcept Therapeutics, Inc. should be less than 10%
Overall Portfolio exposure to Pharmaceuticals & Biotechnology should be less than 30%

(If sector exposure > 30%, please use optimiser tool to see which are the best stocks to hold in Pharmaceuticals & Biotechnology)

When to exit? - We will constantly monitor the company and suggest at the appropriate time to exit from the stock

Is Corcept Therapeutics, Inc. for you?

High Risk, Medium Return

Absolute

Risk Adjusted

Volatility

Corcept Therapeutics, Inc.

-35.84%

0.13

136.44%

S&P 500

30.64%

0.62

19.30%

Quality

Management Risk

Growth

Capital Structure

Quality grade scale :

Below Average, Average, Good, Excellent

Quality key factors

Factor

Value

Sales Growth (5y)

15.79%

EBIT Growth (5y)

-13.15%

EBIT to Interest (avg)

100.00

Debt to EBITDA (avg)

Net Debt to Equity (avg)

-0.47

Sales to Capital Employed (avg)

1.01

Tax Ratio

1.56%

Dividend Payout Ratio

Pledged Shares

Institutional Holding

80.97%

ROCE (avg)

111.37%

ROE (avg)

21.09%

Valuation

Valuation Scorecard

Valuation grade scale :

Very Risky, Risky, Very Expensive, Expensive, Fair, Attractive, Very Attractive

Valuation Key Factors

Factor

Value

P/E Ratio

Industry P/E

Price to Book Value

5.72

EV to EBIT

48.66

EV to EBITDA

47.31

EV to Capital Employed

15.10

EV to Sales

4.30

PEG Ratio

Dividend Yield

ROCE (Latest)

31.04%

ROE (Latest)

16.56%

Technicals

Technical key factors

Indicator

Weekly

Monthly

MACD

Mildly Bullish

Mildly Bearish

RSI

No Signal

Bollinger Bands

Mildly Bearish

Moving Averages

Mildly Bearish (Daily)

KST

Mildly Bullish

Mildly Bearish

Dow Theory

Mildly Bullish

No Trend

OBV

Mildly Bullish

Mildly Bearish

Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish Turned

Technical Movement

Analyse All Technical Factors

Financial Trend

Financial Trend Scorecard

Financial Trend scale:

Very Negative, Negative, Flat, Positive, Very Positive, Outstanding

5What is working for the Company

OPERATING CASH FLOW(Y)

Highest at USD 162.85 MM

RAW MATERIAL COST(Y)

Fallen by 0.66% (YoY

INVENTORY TURNOVER RATIO(HY)

Highest at 1.31 times

NET SALES(Q)

Highest at USD 207.64 MM

-14What is not working for the Company

PRE-TAX PROFIT(Q)

At USD 15.24 MM has Fallen at -51.69%

ROCE(HY)

Lowest at 16.47%

NET PROFIT(Q)

Lowest at USD 19.36 MM

EPS(Q)

Lowest at USD 0.16

Here's what is working for Corcept Therapeutics, Inc.

Operating Cash Flow

Highest at USD 162.85 MM

in the last three years

MOJO Watch

The company has generated higher cash revenues from business operations

Operating Cash Flows (USD MM)

Net Sales

Highest at USD 207.64 MM

in the last five periods

MOJO Watch

Near term sales trend is positive

Net Sales (USD MM)

Inventory Turnover Ratio

Highest at 1.31 times

in the last five Semi-Annual periods

MOJO Watch

Company has been able to sell its inventory faster

Inventory Turnover Ratio

Raw Material Cost

Fallen by 0.66% (YoY)

MOJO Watch

The company's ability to pass on the cost of raw materials to customers has improved; this may lead to a rise in profit margin

Raw Material Cost as a percentage of Sales

Here's what is not working for Corcept Therapeutics, Inc.

Pre-Tax Profit

At USD 15.24 MM has Fallen at -51.69%

over average net sales of the previous four periods of USD 31.55 MM

MOJO Watch

Near term Pre-Tax Profit trend is very negative

Pre-Tax Profit (USD MM)

Net Profit

At USD 19.36 MM has Fallen at -41.33%

over average net sales of the previous four periods of USD 32.99 MM

MOJO Watch

Near term Net Profit trend is very negative

Net Profit (USD MM)

Net Profit

Lowest at USD 19.36 MM

in the last five periods

MOJO Watch

Near term Net Profit trend is negative

Net Profit (USD MM)

EPS

Lowest at USD 0.16

in the last five periods

MOJO Watch

Declining profitability; company has created lower earnings for shareholders

EPS (USD)